Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 2155

Corcept misses primary endpoint in supportive Cushing's syndrome study

$
0
0
Corcept Therapeutics announced Wednesday that its experimental treatment for Cushing’s syndrome missed the primary endpoint in a Phase 3 trial intended to support its FDA submission. While patients with hypertension who received relacorilant in the ...

Viewing all articles
Browse latest Browse all 2155

Trending Articles